


What is claimed is:

1. A peptide characterized by Formula I



Formula I

wherein:

Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R-CO-), wherein R is a hydrophobic moiety, or an aroyl group (Ar-CO-), wherein Ar is an aryl group;

Each of AA<sub>1</sub> and AA<sub>2</sub> are independently selected from the group consisting of no residue, isoleucine (Ile), leucine (Leu), and related alpha-amino acids possessing hydrophobic side-chains;

AA<sub>3</sub> is selected from the group consisting of no residue, glycine (Gly), alanine (Ala) and proline (Pro);

AA<sub>4</sub> is selected from the group consisting of histidine (His), phenylalanine (Phe), tyrosine (Tyr), tryptophan (Trp) and related alpha-amino acids possessing hydrophobic side-chains;

AA<sub>5</sub> is selected from the group consisting of arginine (Arg), ornithine (Orn), lysine (Lys), citrulline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates;

AA<sub>6</sub> is selected from the group consisting of aspartic acid (Asp), asparagine (Asn), glutamic acid (Glu), glutamine (Gln), serine (Ser), 3-amino-5-phenylpentanoic acid and Phe;

AA<sub>7</sub> is selected from the group consisting of no residue, Tyr, Phe, and related alpha-amino acids

possessing hydrophobic side-chains, aromatic amines, aliphatic amines and primary arylalkyl amines;

AA<sub>8</sub> is selected from the group consisting of no residue, Lys, Leu, Tyr, alpha-amino acids possessing hydrophobic side-chains, and aromatic and aliphatic amines;

Z is attached to the carboxy-terminus of said peptide and is selected from the group consisting of, a hydroxyl, NH<sub>2</sub>, and aromatic and aliphatic amines; and functional derivatives thereof.

2. The peptide of claim 1, wherein said acyl group in the definition of Y is selected from the group consisting of benzoyl, acetyl, tert-butyl acetyl, para-phenyl benzoyl, trifluoroacetyl, cyclohexylcarbonyl and phenylacetyl.

3. The peptide of claim 1, wherein said hydrophobic moiety in the definition of Y is selected from the group consisting of a substituted or non-substituted alkyl, a substituted or non-substituted cycloalkyl, a phenylmethyl, and a saturated or unsaturated hydrocarbon chain.

4. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 18 C atoms.

5. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 12 C atoms.

6. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 6 C atoms.

7. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 4 C atoms.

8. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a linear hydrocarbon chain.

9. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is a branched hydrocarbon chain.

10. The peptide of claim 9, wherein said branched hydrocarbon chain has one or two branches.

11. The peptide of claim 9, wherein said branched hydrocarbon chain has one branch.

12. The peptide of claim 3, wherein said substituted or unsubstituted alkyl is an unsaturated hydrocarbon chain having 3 to 18 C atoms.

13. The peptide of claim 12, wherein said unsaturated hydrocarbon chain has at least one double bond and/or at least one triple bond.

14. The peptide of claim 12, wherein said unsaturated hydrocarbon chain has two double bonds.

15. The peptide of claim 12, wherein said unsaturated hydrocarbon chain has one double bond.

16. The peptide of claim 12, wherein said unsaturated hydrocarbon chain has one triple bond.

17. The peptide of claim 3, wherein said substituted alkyl is selected from the group consisting of a mono-, a di-, and a tri-substituted alkyl.

18. The peptide of claim 3, wherein said substituted alkyl is substituted with from 1 to 4 substituents.

19. The peptide of claim 18, wherein said substituent is selected from the group consisting of halo, haloalkyl, hydroxy, aryl, heterocyclyl and heteroaryl.

20. The peptide of claim 19, wherein said aryl is selected from the group consisting of phenyl, tolyl, alkyloxyphenyl, alkyloxycarbonylphenyl, and halophenyl.

21. The peptide of claim 3, wherein said substituted or unsubstituted cycloalkyl is a saturated ring of from 3 to 8 C atoms.

22. The peptide of claim 3, wherein said substituted or unsubstituted cycloalkyl is selected from the group consisting of cyclopentyl and cyclohexyl.

23. The peptide of claim 3, wherein said substituted cycloalkyl is selected from the group consisting of mono- and di-substituted cycloalkyl.

24. The peptide of claim 3, wherein said substituted cycloalkyl has substituents selected from the group consisting of halo, haloalkyl, hydroxy, aryl, heterocyclyl and heteroaryl.

25. The peptide of claim 24, wherein said aryl is selected from the group consisting of phenyl, tolyl, alkoxyphenyl, alkoxycarbonylphenyl and halophenyl.

26. The peptide of claim 3, wherein said saturated or unsaturated hydrocarbon chain is selected from the group consisting of a linear saturated or unsaturated alkyl group, alkenyl group, and branched saturated or unsaturated alkyl group.

27. The peptide of claim 26, wherein said linear saturated alkyl group has from 1 to 18 carbon atoms.

28. The peptide of claim 26, wherein said linear saturated alkyl group has from 1 to 12 carbon atoms.

29. The peptide of claim 26, wherein said linear saturated alkyl group has from 1 to 6 carbon atoms.

30. The peptide of claim 26, wherein said linear saturated alkyl group has from 1 to 4 carbon atoms.

31. The peptide of claim 3, wherein said alkenyl group has 3 to 8 C atoms.

32. The peptide of claim 26, wherein said branched saturated or unsaturated alkyl group has from 3 to 18 C atoms.

33. The peptide of claim 26, wherein said branched saturated or unsaturated alkyl has one or two branches.

34. The peptide of claim 26, wherein said branched saturated or unsaturated alkyl has one branch.

35. The peptide of claim 26, wherein said linear unsaturated alkyl or branched unsaturated alkyl has at least one double bond and/or at least one triple bond.

36. The peptide of claim 26, wherein said linear unsaturated alkyl or branched unsaturated alkyl has two double bonds.

37. The peptide of claim 26, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one double bond.

38. The peptide of claim 26, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one triple bond.

39. The peptide of claim 1, wherein in the definition of AA<sub>4</sub>, said hydrophobic side-chain is selected from the group consisting of cyclohexylalanine and heterocyclic side-chains.

40. The peptide of claim 39, wherein said heterocyclic side-chain is a pyridylalanine group.

41. The peptide of claim 1, wherein in the definition of AA<sub>7</sub>, AA<sub>8</sub> and Z, said aromatic amine is selected from the group consisting of phenylmethanamine, phenylethanamine, phenylpropanamine, and an amine comprising a saturated or unsaturated hydrocarbon chain.

42. The peptide of claim 1, wherein in the definition of AA<sub>7</sub>, AA<sub>8</sub> and Z, said aliphatic amine is selected from the group consisting of amines comprising a saturated or unsaturated hydrocarbon chain.

43. The peptide of claim 41, wherein said amine comprising a saturated or unsaturated hydrocarbon chain is a primary amine.

44. The peptide of any of claims 41 to 43, wherein said saturated or unsaturated hydrocarbon chain is selected from the group consisting of a linear saturated or unsaturated alkyl group, an alkenyl group, and a branched saturated or unsaturated alkyl group.

45. The peptide of claim 44, wherein said linear saturated alkyl group has from 1 to 18 carbon atoms and said linear unsaturated alkyl group has 3 to 18 C atoms.

46. The peptide of claim 44, wherein said linear saturated alkyl group has from 1 to 12 carbon atoms and

said linear unsaturated alkyl group has 3 to 12 C atoms.

47. The peptide of claim 44, wherein said linear saturated alkyl group has from 1 to 6 carbon atoms and said linear unsaturated alkyl group has 3 to 6 C atoms.

48. The peptide of claim 44, wherein said linear saturated alkyl group has from 1 to 4 carbon atoms and said linear unsaturated alkyl group has 3 to 4 C atoms.

49. The peptide of claim 44, wherein said branched saturated or unsaturated alkyl group has from 3 to 18 C atoms.

50. The peptide of claim 44, wherein said branched saturated or unsaturated alkyl has one or two branches.

51. The peptide of claim 44, wherein said branched saturated or unsaturated alkyl has one branch.

52. The peptide of claim 44, wherein said linear unsaturated alkyl or branched unsaturated alkyl has at least one double bond and/or at least one triple bond.

53. The peptide of claim 44, wherein said linear unsaturated alkyl or branched unsaturated alkyl has two double bonds.

54. The peptide of claim 44, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one double bond.



55. The peptide of claim 44, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one triple bond.

56. The peptide of claim 1, wherein in the definitions of AA<sub>1</sub> to AA<sub>8</sub>, said amino acids are D- or L-amino acids.

57. The peptide of claim 1, wherein in the definition of AA<sub>7</sub>, AA<sub>8</sub> and Z, said aromatic amine is a primary aromatic amine.

58. The peptide of claim 1, wherein in the definition of AA<sub>7</sub>, said primary arylalkylamine has a ring of from 6 to 10 C atoms.

59. The peptide of claim 58, wherein in said primary arylalkylamine, said aryl is selected from the group consisting of phenyl, tolyl, alkoxyphenyl, alkoxycarbonylphenyl and halophenyl.

60. The peptide of claim 57, wherein said primary aromatic amine has a ring of from 6 to 10 C atoms.

61. The peptide of claim 1, wherein in the definition of AA<sub>7</sub>, AA<sub>8</sub> and Z said aliphatic amine is a primary aliphatic amine.

62. The peptide of claim 1, wherein said primary aliphatic amine has from 1 to 18 C atoms.

63. The peptide of any one of claims 1 to 62, wherein said peptide is selected from the group consisting of

Sequence (N to C)	SEQ ID NO
ilghrdyk	1
ghrdyk	2
ilgardyk	3
ilghadyk	4
ilgHrayk	6
ilghrDyk	8
ilahradyk	9
ilAhradyk	10
ilghrdyw	11
ilgfrdyk	13
ilghreyk	14
ilghkdyk	15
ilghrnyk	16
ilghr dy	17
ilphrdyk	18
ilhrdyk	19
ilghqdyk	20
ilghrsyk	21
ilghrdy - amide	22
ilghrdyk - amide	23
ilgwr dyk	24
ilgyrdyk	25
ilg -(cha)-rdyk	26
ilg (cha) qdyk	27
ilg (cha) rnyk	28
kydrhgll	29
ilgh - (3PA) - qdyk	30
ilgh -(4PA)-dyk	31
ilgh (cit) dyk	32

and functional derivatives thereof.

64. The peptide of claim 63, wherein said peptide and functional derivatives thereof substantially inhibit FP receptor.
65. The peptide of any one of claims 1 to 64, wherein said FP receptor is from a mammal.
66. The peptide of claim 65, wherein said mammal is a human.
67. The peptide of claim 64, wherein inhibition of FP receptor is measured in a porcine retinal microvascular contraction assay, wherein a contraction caused by prostaglandin  $F_{2\alpha}$  in the presence of the peptide is at least 50% of the contraction produced by the prostaglandin  $F_{2\alpha}$  in the absence of the peptide.
68. The peptide of any of claims 1 to 66, wherein inhibition of FP receptor is measured in a porcine retinal microvascular contraction assay, wherein a contraction caused by prostaglandin  $F_{2\alpha}$  in the presence of the peptide is at least 50% of the contraction produced by the prostaglandin  $F_{2\alpha}$  in the absence of the peptide.
69. A pharmaceutical composition comprising a therapeutically effective amount of at least one peptide of any one of claims 1 to 68 in association with a pharmaceutically acceptable carrier.

70. The pharmaceutical composition of claim 69, wherein said therapeutically effective amount of said at least one peptide is 0.1-100 mg/Kg body weight.

71. Use of at least one peptide according to any one of claims 1 to 68, alone or in combination with a pharmaceutically acceptable carrier, to inhibit FP receptor.


72. Use of the pharmaceutical composition of claim 69 or claim 70 for the preparation of a medicament to arrest preterm labor.

73. Use of the pharmaceutical composition of claim 69 or claim 70 for the preparation of a medicament for the treatment of dysmenorrhea.

74. A method of arresting preterm labor comprising administering to an individual a therapeutically effective amount of the pharmaceutical composition of claim 69 or claim 70.

75. A method of treating dysmenorrhea comprising administering to an individual a therapeutically effective amount of the pharmaceutical composition of claim 69 or claim 70.

76. A peptidomimetic characterized by Formula II:



Formula II

wherein:

Y is attached to the amino-terminus of said peptide and is selected from the group consisting of a hydrogen atom, an acyl group (R-CO-), wherein R is a hydrophobic moiety, or an aroyl group (Ar-CO-), wherein Ar is an aryl group;

BTM (beta turn mimetic) is a dipeptide surrogate;

AA<sub>1</sub> is selected from the group consisting of Arg, Orn, Lys, citruline, 2-, 3-, and 4-pyridylalanine, and arginine surrogates;

AA<sub>2</sub> is selected from the group consisting of Asp, Asn, Glu, Gln, Ser, 3-amino-5-phenylpentanoic acid and Phe;

AA<sub>3</sub> is selected from the group consisting of no residue, Tyr, Phe, and related alpha-amino acids possessing hydrophobic side-chains, and aromatic amines, aliphatic amines and primary arylalkyl amines;

Z is selected from the group consisting of no residue, a hydroxyl group, NH<sub>2</sub>, and aromatic, heteroaromatic and aliphatic amines; and

functional derivatives thereof.

77. The peptidomimetic of claim 76, wherein said acyl group in the definition of Y is selected from the group consisting of benzoyl, acetyl, tert-butyl acetyl, para-phenyl benzoyl, trifluoroacetyl, cyclohexylcarbonyl and phenylacetyl.

78. The peptidomimetic of claim 76, wherein said hydrophobic moiety in the definition of Y is selected from the group consisting of a substituted or non-

substituted alkyl, a substituted or non-substituted cycloalkyl, a phenylmethyl, and a saturated or unsaturated hydrocarbon chain.

79. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 18 C atoms.

80. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 12 C atoms.

81. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 6 C atoms.

82. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a saturated hydrocarbon chain having from 1 to 4 C atoms.

83. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a linear hydrocarbon chain.

84. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is a branched hydrocarbon chain.

85. The peptidomimetic of claim 84, wherein said branched hydrocarbon chain has one or two branches.

86. The peptidomimetic of claim 84, wherein said branched hydrocarbon chain has one branch.

87. The peptidomimetic of claim 78, wherein said substituted or unsubstituted alkyl is an unsaturated hydrocarbon chain having from 3 to 18 C atoms.

88. The peptidomimetic of claim 87, wherein said unsaturated hydrocarbon chain has at least one double bond and/or at least one triple bond.

89. The peptidomimetic of claim 87, wherein said unsaturated hydrocarbon chain has two double bonds.

90. The peptidomimetic of claim 87, wherein said unsaturated hydrocarbon chain has one double bond.

91. The peptidomimetic of claim 87, wherein said unsaturated hydrocarbon chain has one triple bond.

92. The peptidomimetic of claim 78, wherein said substituted alkyl is selected from the group consisting of a mono-, a di-, and a tri-substituted alkyl.

93. The peptidomimetic of claim 78, wherein said substituted alkyl is substituted with from 1 to 4 substituents.

94. The peptidomimetic of claim 93, wherein said substituent is selected from the group consisting of halo, haloalkyl, hydroxy, aryl, heterocyclyl and heteroaryl.

95. The peptidomimetic of claim 93, wherein said aryl is selected from the group consisting of phenyl, tolyl, alkyloxyphenyl, alkyloxycarbonylphenyl, and halophenyl.

96. The peptidomimetic of claim 78, wherein said substituted or unsubstituted cycloalkyl is a saturated ring of from 3 to 8 C atoms.

97. The peptidomimetic of claim 78, wherein said substituted or unsubstituted cycloalkyl is selected from the group consisting of cyclopentyl and cyclohexyl.

98. The peptidomimetic of claim 78, wherein said substituted cycloalkyl is selected from the group consisting of mono- and di-substituted cycloalkyl.

99. The peptidomimetic of claim 78, wherein said substituted cycloalkyl has substituents selected from the group consisting of halo, haloalkyl, hydroxy, aryl, heterocyclyl and heteroaryl.

100. The peptidomimetic of claim 99, wherein said aryl is selected from the group consisting of phenyl, tolyl, alkoxyphenyl, alkoxycarbonylphenyl and halophenyl.

101. The peptidomimetic of claim 78, wherein said saturated or unsaturated hydrocarbon chain is selected from the group consisting of a linear saturated or unsaturated alkyl group, an alkenyl group, and a branched saturated or unsaturated alkyl group.



102. The peptidomimetic of claim 101, wherein said linear saturated alkyl group has from 1 to 18 carbon atoms.

103. The peptidomimetic of claim 101, wherein said linear saturated alkyl group has from 1 to 12 carbon atoms.

104. The peptidomimetic of claim 101, wherein said linear saturated alkyl group has from 1 to 6 carbon atoms.

105. The peptidomimetic of claim 101, wherein said linear saturated alkyl group has from 1 to 4 carbon atoms.

106. The peptidomimetic of claim 101, wherein said alkenyl group has 3 to 8 C atoms.

107. The peptidomimetic of claim 101, wherein said branched saturated or unsaturated alkyl group has from 3 to 18 C atoms.

108. The peptidomimetic of claim 101, wherein said branched saturated or unsaturated alkyl has one or two branches.

109. The peptidomimetic of claim 101, wherein said branched saturated or unsaturated alkyl has one branch.

110. The peptidomimetic of claim 101, wherein said linear unsaturated alkyl or branched unsaturated alkyl

has at least one double bond and/or at least one triple bond.

111. The peptidomimetic of claim 101, wherein said linear unsaturated alkyl or branched unsaturated alkyl has two double bonds.

112. The peptidomimetic of claim 101, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one double bond.

113. The peptidomimetic of claim 100, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one triple bond.

114. The peptidomimetic of claim 76, wherein in the definition of AA<sub>3</sub> and Z, said aliphatic amine is selected from the group consisting of amines comprising a saturated or unsaturated hydrocarbon chain.

115. The peptidomimetic of claim 114, wherein said amine comprising a saturated or unsaturated hydrocarbon chain is a primary amine.

116. The peptidomimetic of claim 114 or claim 115, wherein said saturated or unsaturated hydrocarbon chain is selected from the group consisting of a linear saturated or unsaturated alkyl group, an alkenyl group, and a branched saturated or unsaturated alkyl group.

117. The peptidomimetic of claim 116, wherein said linear saturated alkyl group has from 1 to 18 carbon

atoms and said linear unsaturated alkyl group has 3 to 18 C atoms.

118. The peptidomimetic of claim 116, wherein said linear saturated alkyl group has from 1 to 12 carbon atoms and said linear unsaturated alkyl group has 3 to 12 C atoms.

119. The peptidomimetic of claim 116, wherein said linear saturated alkyl group has from 1 to 6 carbon atoms and said linear unsaturated alkyl group has 3 to 6 C atoms.

120. The peptidomimetic of claim 116, wherein said linear saturated alkyl group has from 1 to 4 carbon atoms and said linear unsaturated alkyl group has 3 to 4 C atoms.

121. The peptidomimetic of claim 116, wherein said branched saturated or unsaturated alkyl group has from 3 to 18 C atoms.

122. The peptidomimetic of claim 116, wherein said branched saturated or unsaturated alkyl has one or two branches.

123. The peptidomimetic of claim 116, wherein said branched saturated or unsaturated alkyl has one branch.

124. The peptidomimetic of claim 116, wherein said linear unsaturated alkyl or branched unsaturated alkyl

has at least one double bond and/or at least one triple bond.

125. The peptidomimetic of claim 116, wherein said linear unsaturated alkyl or branched unsaturated alkyl has two double bonds.

126. The peptidomimetic of claim 116, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one double bond.

127. The peptidomimetic of claim 116, wherein said linear unsaturated alkyl or branched unsaturated alkyl has one triple bond.

128. The peptidomimetic of claim 76, wherein in the definitions of AA<sub>1</sub> to AA<sub>3</sub>, said amino acids are D- or L-amino acids.

129. The peptidomimetic of claim 76, wherein in the definition of AA<sub>3</sub> and Z, said aromatic amine is a primary aromatic amine.

130. The peptidomimetic of claim 76, wherein in the definition of AA<sub>3</sub>, said primary arylalkyl has a ring of from 6 to 10 C atoms.

131. The peptidomimetic of claim 130, wherein in said primary arylalkyl, said aryl is selected from the group consisting of phenyl, tolyl, alkoxyphenyl, alkoxycarbonylphenyl and halophenyl.

132. The peptidomimetic of claim 129, wherein said primary aromatic amine has a ring of from 6 to 10 C atoms.

133. The peptidomimetic of claim 76, wherein in the definition of AA<sub>3</sub> and Z said aliphatic amine is a primary aliphatic amine.

134. The peptidomimetic of claim 76, wherein said primary aliphatic amine has from 1 to 10 C atoms.

135. The peptidomimetic of any one of claims 76 to 134, wherein said peptidomimetic is selected from the group consisting of

Structure	Compound No.
Y1-BnIAA-RD-Z1	33
Y1-BnIAA-RD-Z2	34
Y2-BnIAA-RD-Z1	35
Y2-BnIAA-RD-Z2	36
Y2-BnIAA-RD-Z3	37
Y2-BnIAA-RD-Z4	38
Y3-BnIAA-RD-Z2	39
Y2-IAA-RD-Z3	40
Y2-BnIAA-R-Z5	41
Y2-BnIAA-R-Z6	42
Y2-BnIAA-R-Z7	43
Y2-BnIAA-R-Z9	44
Y2-IAA-R-Z8	45
Y2-IAA-R-Z5	46
Y2-IAA-R-Z9	47
Y2-IAA-R-Z7	48
Y2-IAA-R-Z6	49
Y2-IAA-(Cit)-Z9	50

Y2-IAA(3PA)-Z9	51
Y2-IAA-(4PA)-Z9	52

and functional derivatives thereof.

136. The peptidomimetic of claim 135, wherein said peptidomimetic and functional derivatives thereof substantially inhibit FP receptor.

137. The peptidomimetic of any one of claims 76 to 136, wherein said FP receptor is from a mammal.

138. The peptidomimetic of claim 137, wherein said mammal is a human.

139. The peptidomimetic of claim 136, wherein inhibition of FP receptor is measured in a porcine retinal microvascular contraction assay, wherein a contraction caused by prostaglandin  $F_{2\alpha}$  in the presence of the peptidomimetic is at least 50% of the contraction produced by the prostaglandin  $F_{2\alpha}$  in the absence of the peptidomimetic.

140. The peptidomimetic of any of claims 76 to 138, wherein inhibition of FP receptor is measured in a porcine retinal microvascular contraction assay, wherein a contraction caused by prostaglandin  $F_{2\alpha}$  in the presence of the peptidomimetic is at least 50% of the contraction produced by the prostaglandin  $F_{2\alpha}$  in the absence of the peptidomimetic.

141. A pharmaceutical composition comprising a therapeutically effective amount of at least one peptidomimetic of any one of claims 76 to 140 in association with a pharmaceutically acceptable carrier.

142. The pharmaceutical composition of claim 141, wherein said therapeutically effective amount of said at least one peptidomimetic is 0.1-100 mg/Kg body weight.

143. Use of at least one peptidomimetic according to any one of claims 76 to 140, alone or in combination with a pharmaceutically acceptable carrier, to inhibit FP receptor.

144. Use of the pharmaceutical composition of claim 141 or claim 142 for the preparation of a medicament to arrest preterm labor.

145. Use of the pharmaceutical composition of claim 141 or claim 142 for the preparation of a medicament for the treatment of dysmenorrhea.

146. A method of arresting preterm labor comprising administering to an individual a therapeutically effective amount of the pharmaceutical composition of claim 141 or claim 142.

147. A method of treating dysmenorrhea comprising administering to an individual a therapeutically effective amount of the pharmaceutical composition of claim 141 or claim 142.

148. The peptidomimetic of claim 76, wherein said dipeptide surrogate is selected from the group consisting of indolizidinone amino acids, 5- and 7-alkyl-branched indolizidinone amino acids, quinolizidinone amino acids, pyrroloazepinone amino acids, azabicyclo[X.Y.0]alkanone amino acids, heterocyclic and carbocyclic moieties, mimics of beta-turn structure and lactam analogs.